FindMyKOL
Clinical trialNCT03073525CompletedPhase 2Interventional

A Trial of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers

SponsorGradalis, Inc.Enrollment25Advanced Gynecological CancersCervical CancerOvarian CancerUterine Cancer
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The clinical trial was a companion study to protocol CL-PTL-119 (A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Vigil Engineered Autologous Tumor Cell Immunotherapy in Subjects with Stage IIIb-IV Ovarian Cancer in Clinical Complete Response following Surgery and Primary Chemotherapy (VITAL) NCT02346747). Participants who had investigational product (Vigil) successfully made but were not eligible to enroll onto the VITAL study or previously randomized to placebo were given the opportunity to participate in this protocol. The main goal of this clinical trial was to determine the safety of combining Vigil therapy with atezolizumab.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • University of South Alabama Mitchell Cancer Institute

    Mobile, Alabama, United States

  • Georgia Cancer Center at Augusta University

    Augusta, Georgia, United States

  • Henry Ford Hospital

    Detroit, Michigan, United States

  • Billings Clinic

    Billings, Montana, United States

  • Dartmouth-Hitchcock Medical Center/ Norris Cotton Cancer Center

    Lebanon, New Hampshire, United States

  • Prisma Health Cancer Institute

    Greenville, South Carolina, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Atezolizumab →Vigil
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
31 May 2017
Primary completion
22 May 2019
Completion
18 May 2022
Last update posted
5 Apr 2023
Registered enrollment
25
Registry id
NCT03073525
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.